BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7(26): 2676-2680 [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830 [PMID: 34447228 DOI: 10.3748/wjg.v27.i29.4818] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nguyen LT, Van Nguyen D, Carr MJ, Hall WW, Nguyen LA. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Arch Virol 2018;163:115-24. [PMID: 29022122 DOI: 10.1007/s00705-017-3583-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Naz Z, Wahid B, Usman S, Saleem K, Rafique S, Ali A, Idrees M. Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. J Interferon Cytokine Res 2018;38:255-60. [PMID: 29920131 DOI: 10.1089/jir.2017.0138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Mapoure NY, Budzi MN, Eloumou SAFB, Malongue A, Okalla C, Luma HN. Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study. PLoS One. 2018;13:e0192406. [PMID: 29513678 DOI: 10.1371/journal.pone.0192406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Omran D, Zayed RA, Nabeel MM, Mobarak L, Zakaria Z, Farid A, Hassany M, Saif S, Mostafa M, Saad OK, Yosry A. Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients. Viral Immunol 2018;31:315-20. [PMID: 29630460 DOI: 10.1089/vim.2017.0134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Zheng X, Guo R, Liu Q, Wakae K, Watanabe N, Fukano K, Que L, Li Y, Aly HH, Watashi K, Suzuki R, Murayama A, Kato T, Aizaki H, Wakita T, Huang X, Yan Y, Song SJ, Muramatsu M. Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus. Biochem Biophys Res Commun 2021;567:1-8. [PMID: 34130179 DOI: 10.1016/j.bbrc.2021.06.022] [Reference Citation Analysis]
7 Gull I, Aslam MS, Tipu I, Mushtaq R, Ali TZ, Athar MA. Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection. Sci Rep 2019;9:10867. [PMID: 31350425 DOI: 10.1038/s41598-019-47074-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Townshend-Bulson L, Roik E, Barbour Y, Bruden DJT, Homan CE, Espera HGF, Stevenson TJ, Hewitt AM, Rhodes W, Gove JE, Plotnik JN, Snowball MM, McGilvray J, Simons BC, Johnston JM, McMahon BJ. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. PLoS One 2021;16:e0260970. [PMID: 34855920 DOI: 10.1371/journal.pone.0260970] [Reference Citation Analysis]
9 Nguyen LP, Park C, Luong TTD, Park EM, Choi DH, Han KM, Mai HN, Nguyen HC, Lim YS, Hwang SB. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry. Sci Rep 2019;9:7288. [PMID: 31086268 DOI: 10.1038/s41598-019-43783-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep 2020;3:e145. [PMID: 32270053 DOI: 10.1002/hsr2.145] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yang X, Ye Y, Wang T, Li M, Yu L, Xia M, Qian J, Hu Z. Eu3+ /Sm3+ dual-label time-resolved fluoroimmunoassay for measurement of hepatitis C virus antibodies. J Clin Lab Anal 2019;33:e22659. [PMID: 30152027 DOI: 10.1002/jcla.22659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol 2018;31:35-41. [PMID: 29333065 DOI: 10.20524/aog.2017.0204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol 2017; 23(21): 3815-3824 [PMID: 28638221 DOI: 10.3748/wjg.v23.i21.3815] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
14 Barros MMO, Ronchini KROM, Soares RLS. HEPATITIS B AND C IN PREGNANT WOMEN ATTENDED BY A PRENATAL PROGRAM IN AN UNIVERSITARY HOSPITAL IN RIO DE JANEIRO, BRAZIL: RETROSPECTIVE STUDY OF SEROPREVALENCE SCREENING. Arq Gastroenterol 2018;55:267-73. [PMID: 30540090 DOI: 10.1590/S0004-2803.201800000-68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Wahid B, Rafique S, Saleem K, Ali A, Idrees M. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. Journal of Interferon & Cytokine Research 2018;38:122-8. [DOI: 10.1089/jir.2017.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Qin L, Zhou YC, Wu HJ, Zhuo Y, Wang YP, Si CY, Qin YM. Notch Signaling Modulates the Balance of Regulatory T Cells and T Helper 17 Cells in Patients with Chronic Hepatitis C. DNA Cell Biol 2017;36:311-20. [PMID: 28157396 DOI: 10.1089/dna.2016.3609] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
17 Atapour A, Mokarram P, Mostafavipour Z, Hosseini SY, Ghasemi Y, Mohammadi S, Nezafat N. Designing a Fusion Protein Vaccine Against HCV: An In Silico Approach. Int J Pept Res Ther 2019;25:861-72. [DOI: 10.1007/s10989-018-9735-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Behzadifar M, Heydarvand S, Behzadifar M, Bragazzi NL. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci 2019;29:945-56. [PMID: 30700963 DOI: 10.4314/ejhs.v29i1.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
19 Adekunle AD, Harp KL, Al-Abdali ZG, Critchfield AS, Barnhart S, Winter KT. Reported Barriers to Hepatitis C Treatment among Pregnant and Early-Parenting Mothers Undergoing Substance Use Disorder Treatment in One U.S. State. Infect Dis Rep 2021;14:1-11. [PMID: 35076528 DOI: 10.3390/idr14010001] [Reference Citation Analysis]
20 Amer T, El-baz R, Mokhtar A, El-shaer S, Elshazli R, Settin A. Genetic polymorphisms of IL-23R (rs7517847) and LEP (rs7799039) among Egyptian patients with hepatocellular carcinoma. Archives of Physiology and Biochemistry 2017;123:279-85. [DOI: 10.1080/13813455.2017.1320680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
21 Jun HJ, DeVylder JE, Fedina L. Police Violence among Adults Diagnosed with Mental Disorders. Health Soc Work 2020;45:81-9. [PMID: 32393967 DOI: 10.1093/hsw/hlaa003] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Toson EA, Shiha GE, Abdelgaleel AE. Fibrogenic/Angiogenic Linker for Non-Invasive Assessment of Hepatic Fibrosis Staging in Chronic Hepatitis C Among Egyptian Patients. Ann Hepatol 2017;16:862-73. [PMID: 29055924 DOI: 10.5604/01.3001.0010.5276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zhang J, Huang Z, Liu X, Wu C, Zhou W, Ye P, Stalin A, Lu S, Tan Y, Wu Z, Fan X, Zhang X, Wang M, Li B, Cheng G, Mou Y, Wu J, Wan S. Exploring the Multicomponent Synergy Mechanism of Yinzhihuang Granule in Inhibiting Inflammation-Cancer Transformation of Hepar Based on Integrated Bioinformatics and Network Pharmacology. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/6213865] [Reference Citation Analysis]
24 Wang RY, Bare P, De Giorgi V, Matsuura K, Salam KA, Grandinetti T, Schechterly C, Alter HJ. Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system. Hepatology 2016;64:1900-10. [PMID: 27641977 DOI: 10.1002/hep.28842] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
25 Salmi L, Barbaglia MN, Smirne C, Bianco S, Guaschino G, Crobu MGS, Minisini R, Pirisi M. Detrimental Impact of Interferon-Based Regimens for Chronic Hepatitis C on Vitamin D/Parathyroid Hormone Homeostasis. TORJ 2018;12:279-88. [DOI: 10.2174/1874312901812010279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
27 Marciano S, Haddad L, Plazzotta F, Mauro E, Terraza S, Arora S, Thornton K, Ríos B, García Dans C, Ratusnu N, Calanni L, Allevato J, Sirotinsky ME, Pedrosa M, Gadano A. Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C. J Med Virol 2017;89:660-4. [PMID: 27551942 DOI: 10.1002/jmv.24668] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
28 Permanasari AA, Aoki-Utsubo C, Wahyuni TS, Tumewu L, Adianti M, Widyawaruyanti A, Hotta H, Hafid AF. An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs. BMC Complement Med Ther 2021;21:260. [PMID: 34641875 DOI: 10.1186/s12906-021-03408-w] [Reference Citation Analysis]
29 Beaulieu T, Hayashi K, Milloy MJ, Nosova E, DeBeck K, Montaner J, Kerr T, Ti L. HIV Serostatus and Having Access to a Physician for Regular Hepatitis C Virus Care Among People Who Inject Drugs. J Acquir Immune Defic Syndr 2018;78:93-8. [PMID: 29630030 DOI: 10.1097/QAI.0000000000001651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Singh P, Dass JFP. Nearly neutral evolution in IFNL3 gene retains the immune function to detect and clear the viral infection in HCV. Prog Biophys Mol Biol 2018;140:107-16. [PMID: 29746888 DOI: 10.1016/j.pbiomolbio.2018.05.004] [Reference Citation Analysis]
31 Triantos C, Konstantakis C, Tselekouni P, Kalafateli M, Aggeletopoulou I, Manolakopoulos S. Epidemiology of hepatitis C in Greece. World J Gastroenterol 2016;22:8094-102. [PMID: 27688651 DOI: 10.3748/wjg.v22.i36.8094] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zhang AM, Zhang CL, Song Y, Zhao P, Feng Y, Wang B, Li Z, Liu L, Xia X. Genetic variations of the NPC1L1 gene associated with hepatitis C virus (HCV) infection and biochemical characteristics of HCV patients in China. Int J Infect Dis 2016;53:6-11. [PMID: 27769799 DOI: 10.1016/j.ijid.2016.10.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
33 Bahrami MT, Mohammadi B, Miraghaei S, Babaei A, Ghaheri M, Bahrami G. Quantification of sofosbuvir in human serum by liquid chromatography with negative ionization mass spectrometry using the parent peak and its source-induced fragment: Application to a bioequivalence study. J Sep Sci 2016;39:2702-9. [PMID: 27257162 DOI: 10.1002/jssc.201501375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Saleem K, Wahid B, Ali A, Rafique S, Naz Z, Usman S, Idrees M. Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports. Viral Immunol 2018;31:480-3. [PMID: 29694794 DOI: 10.1089/vim.2017.0199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Misra S, Dieterich DT, Saberi B, Kushner T. Direct-acting antiviral treatment of acute hepatitis C virus infections. Expert Rev Anti Infect Ther 2018;16:599-610. [PMID: 30067402 DOI: 10.1080/14787210.2018.1505502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Patil VS, Harish DR, Vetrivel U, Roy S, Deshpande SH, Hegde HV. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective. Molecules 2022;27:1076. [DOI: 10.3390/molecules27031076] [Reference Citation Analysis]
37 Wahid B, Waqar M, Saleem K, Shafi F, Rehman Z, Hanif I, Ahmad HM, Wasim M, Sajjad, Wahid K, Idrees M. Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert ® technology. Future Virology 2018;13:467-74. [DOI: 10.2217/fvl-2017-0158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Alduraywish A, Ragheb M, Taher I, Louis N, Aldossari K, Kishk R. Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study. Scand J Gastroenterol 2020;55:963-9. [PMID: 32649843 DOI: 10.1080/00365521.2020.1790649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Sempere RN, Arias A. Establishment of a Cell Culture Model of Persistent Flaviviral Infection: Usutu Virus Shows Sustained Replication during Passages and Resistance to Extinction by Antiviral Nucleosides. Viruses 2019;11:E560. [PMID: 31212939 DOI: 10.3390/v11060560] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
40 Magri A, Mokrane O, Lauder K, Patel AH, Castagnolo D. Synthesis, biological evaluation and mode of action studies of novel amidinourea inhibitors of hepatitis C virus (HCV). Bioorg Med Chem Lett 2019;29:724-8. [PMID: 30661824 DOI: 10.1016/j.bmcl.2019.01.008] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Lee J, Chan ST, Kim JY, Ou JJ. Hepatitis C Virus Induces the Ubiquitin-Editing Enzyme A20 via Depletion of the Transcription Factor Upstream Stimulatory Factor 1 To Support Its Replication. mBio 2019;10:e01660-19. [PMID: 31337730 DOI: 10.1128/mBio.01660-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Marrie TJ, Tyrrell GJ, Majumdar SR, Eurich DT. Concurrent Infection with Hepatitis C Virus and Streptococcus pneumoniae. Emerg Infect Dis 2017;23:1118-23. [PMID: 28628455 DOI: 10.3201/eid2307.161858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
43 Dawood RM, Moustafa RI, Abdelhafez TH, El-Shenawy R, El-Abd Y, Bader El Din NG, Dubuisson J, El Awady MK. A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. BMC Infect Dis 2019;19:932. [PMID: 31690267 DOI: 10.1186/s12879-019-4571-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
44 Boushi E, Cheha K, Hedar N, Almokdad R, Alassi MW, Kakaje A. Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00150-3] [Reference Citation Analysis]
45 Wyżewski Z, Świtlik W, Mielcarska MB, Gregorczyk-Zboroch KP. The Role of Bcl-xL Protein in Viral Infections. Int J Mol Sci 2021;22:1956. [PMID: 33669408 DOI: 10.3390/ijms22041956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Jie Y, Lin C, Yuan J, Zhao Z, Guan Y, Zhou Y, Zhou X, Zhong B, Ye Y, Zhang L, Tao L, Li J, Zhang X, Chong Y. Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study. Liver Research 2020;4:153-8. [DOI: 10.1016/j.livres.2020.06.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Tai CJ, Jassey A, Liu CH, Tai CJ, Richardson CD, Wong SH, Lin LT. Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. Cells 2020;9:E908. [PMID: 32276448 DOI: 10.3390/cells9040908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Xuan W, Song D, Yan Y, Yang M, Sun Y, Guaragnella N. A Potential Role for Mitochondrial DNA in the Activation of Oxidative Stress and Inflammation in Liver Disease. Oxidative Medicine and Cellular Longevity 2020;2020:1-10. [DOI: 10.1155/2020/5835910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
49 Rafiq S, Majeed MI, Nawaz H, Rashid N, Yaqoob U, Batool F, Bashir S, Akbar S, Abubakar M, Ahmad S, Ali S, Kashif M, Amin I. Surface-enhanced Raman spectroscopy for analysis of PCR products of viral RNA of hepatitis C patients. Spectrochim Acta A Mol Biomol Spectrosc 2021;259:119908. [PMID: 33989976 DOI: 10.1016/j.saa.2021.119908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Miri HH, Fazeli P, Ali-Hassanzadeh M, Bemani P, Kabelitz D, Kalantar K. Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis. Arch Virol 2021;166:2469-78. [PMID: 34216268 DOI: 10.1007/s00705-021-05141-8] [Reference Citation Analysis]
51 Munyemana JB, Mukanoheli E, Nsabimana T, Niringiyumukiza JD. HCV Seroprevalence among HIV Patients and Associated Comorbidities at One Primary Health Facility in Rwanda. Am J Trop Med Hyg 2021:tpmd200500. [PMID: 33720846 DOI: 10.4269/ajtmh.20-0500] [Reference Citation Analysis]
52 Fu J, Li Y, Li Z, Li N. Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma. Biosci Rep 2018;38:BSR20180044. [PMID: 29717027 DOI: 10.1042/BSR20180044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
53 Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities. South Afr J HIV Med 2018;19:737. [PMID: 29707384 DOI: 10.4102/sajhivmed.v19i1.737] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
54 Lee JC, Lin CK, Tseng CK, Chen YL, Tzeng CC, Tseng CH. Discovery of 3-Amino-2-Hydroxypropoxyisoflavone Derivatives as Potential Anti-HCV Agents. Molecules 2018;23:E2863. [PMID: 30400244 DOI: 10.3390/molecules23112863] [Reference Citation Analysis]
55 Shukla N, Angelopoulou A, Hodhod R. Non-Invasive Diagnosis of Liver Fibrosis in Chronic Hepatitis C using Mathematical Modeling and Simulation. Electronics 2022;11:1260. [DOI: 10.3390/electronics11081260] [Reference Citation Analysis]
56 Lee YC, Wang JL, Dong YH, Chen HC, Wu LC, Chang CH. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study. PLoS Med 2019;16:e1002894. [PMID: 31518344 DOI: 10.1371/journal.pmed.1002894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Gad M, Hassan SA, Zaazaa HE, Amer SM. Multivariate Development and Optimization of Stability Indicating Method for Determination of Daclatasvir in Presence of Potential Degradation Products. Chromatographia 2019;82:1641-52. [DOI: 10.1007/s10337-019-03793-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Paul C, Khera L, Kaul R. Hepatitis C virus core protein interacts with cellular metastasis suppressor Nm23-H1 and promotes cell migration and invasion. Arch Virol 2019;164:1271-85. [PMID: 30859475 DOI: 10.1007/s00705-019-04151-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Laugi H. Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine. Euroasian J Hepatogastroenterol 2020;10:105-8. [PMID: 33511075 DOI: 10.5005/jp-journals-10018-1326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol 2016;88:2170-8. [PMID: 27183377 DOI: 10.1002/jmv.24575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
61 Serai SD, Yin M. MR Elastography of the Abdomen: Basic Concepts. In: Pohlmann A, Niendorf T, editors. Preclinical MRI of the Kidney. New York: Springer US; 2021. pp. 301-23. [DOI: 10.1007/978-1-0716-0978-1_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Alsalawy NF, Darwish RK, Kamal MM, ElTaweel AE, Shousha HI, Elbaz TM. Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma. J Med Virol 2018;90:490-6. [PMID: 28975649 DOI: 10.1002/jmv.24964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]